{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:12:41Z","timestamp":1770441161567,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.leukres.2014.04.004","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T12:38:30Z","timestamp":1397824710000},"page":"781-787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Chronic myeloid leukemia patients who develop grade I\/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"Eskazan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Eyice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enes Ali","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugrul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi Firat","family":"Yalniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse","family":"Salihoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seniz","family":"Ongoren Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Baslar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burhan","family":"Ferhanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yildiz","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nukhet","family":"Tuzuner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Ozbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teoman","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.leukres.2014.04.004_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.leukres.2014.04.004_bib0010","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/11207580-000000000-00000","article-title":"Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"71","author":"McCormack","year":"2011","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.leukres.2014.04.004_bib0015","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.leukres.2014.04.004_bib0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4274\/Tjh.2013.0151","article-title":"Turkish chronic myeloid leukemia study: retrospective sectional analysis of CML patients","volume":"30","author":"Sahin","year":"2013","journal-title":"Turk J Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2014.04.004_bib0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond","volume":"47","author":"La Ros\u00e9e","year":"2010","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.leukres.2014.04.004_bib0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2014.04.004_bib0035","doi-asserted-by":"crossref","DOI":"10.4161\/cbt.27310","article-title":"Large granular lymphocytosis during dasatinib therapy","volume":"15","author":"Qiu","year":"2013","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.leukres.2014.04.004_bib0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","article-title":"Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?","volume":"89","author":"Paydas","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.leukres.2014.04.004_bib0045","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.leukres.2014.04.004_bib0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2741.2741","article-title":"The association of dasatinib-induced lymphocytosis with treatment outcome in patients with chronic myeloid leukemia (CML)","volume":"122","author":"Schiffer","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2014.04.004_bib0055","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-011-0921-9","article-title":"Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy","volume":"94","author":"Kim","year":"2011","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.leukres.2014.04.004_bib0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2010.030494","article-title":"Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100mg or 50mg daily","volume":"96","author":"Krauth","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2014.04.004_bib0065","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3324\/haematol.2011.040048","article-title":"Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy","volume":"96","author":"Eskazan","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.leukres.2014.04.004_bib0070","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.04.004_bib0075","series-title":"WHO classification of tumors of hematopoietic and lymphoid tissues","first-page":"32","article-title":"Chronic myelogenous leukemia BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"issue":"3","key":"10.1016\/j.leukres.2014.04.004_bib0080","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.leukres.2014.04.004_bib0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"21","key":"10.1016\/j.leukres.2014.04.004_bib0090","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.leukres.2014.04.004_bib0095","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","article-title":"Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion","volume":"91","author":"Nagata","year":"2010","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.leukres.2014.04.004_bib0100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"Lavallade","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.leukres.2014.04.004_bib0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukaemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2014.04.004_bib0110","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukaemia","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"25","key":"10.1016\/j.leukres.2014.04.004_bib0115","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myeloid leukemia treated ith dasatinib after imatinib failure","volume":"25","author":"Quint\u00e2s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.leukres.2014.04.004_bib0120","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140mg once daily versus 70mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2014.04.004_bib0125","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.leukres.2010.08.022","article-title":"Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib","volume":"35","author":"Valent","year":"2011","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.leukres.2014.04.004_bib0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2014.04.004_bib0135","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.21980","article-title":"Retrospective multicenter study on the development on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukaemia","volume":"86","author":"Lee","year":"2011","journal-title":"Am J Hematol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614001155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T01:05:01Z","timestamp":1597712701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614001155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0145212614001155"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.04.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myeloid leukemia patients who develop grade I\/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}